In: Iqbal, N., Khan, N.A., Ferrante, A
Antioxidants 8 , 72 (2019)
doi: 10.3390/ijms20102407 136 RodopuloAK
Etanercept given every week subcutaneously Adalimumab given every 2 weeks subcutaneously Infliximab given every 6 to 8 weeks intravenously Certolizumab pegol given every 2 to 4 weeks subcutaneously Golimumab given monthly subcutaneously Simponi ARIA given every 8 weeks intravenously There are other, less common biologic agents that can interrupt the inflammatory process, including: Tocilizumab (Actemra) Sarilumab (Kevzara) Abatacept (Orencia) These too, are given either subcutaneously or through IV every few weeks
Emerging evidence indicates that dependence can be shaped by metastatic niche, antioxidant nutrient availability and tumor genotype (for example, NRF2/KEAP1 signaling, baseline GPX4 expression and lipid composition)